Jeffrey Crowley

62000 Impact of High Skin Clearance on Psychosocial Outcomes and Symptoms Associated With Psoriasis: Pooled Results From the UltIMMa 1 & 2 Studies

Jeffrey Crowley, Saakshi Khattri, Bruce E Strober, Cuiyong Yue et autres

50668 Long-term Impact of Apremilast on Cardiometabolic Parameters and the Relationship of Cardiometabolic Changes With Psoriasis Efficacy

Bruce E Strober, Jeffrey Crowley, Richard G B Langley, Cynthia Deignan et autres

us, ca (code pays fourni par la source)

51109 Efficacy of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in scalp psoriasis by baseline Psoriasis Area and Severity Index (PASI) and baseline body surface area (BSA): A subanalysis of the phase 3 clinical trial data

Andrew Blauvelt, Howard L. Sofen, Jo Lambert, Joseph Frank Merola et autres

us, be (code pays fourni par la source)

Steroid-sparing effect of risankizumab vs ustekinumab in patients with moderately to severely active Crohn’s disease: Post hoc results from the phase 3b SEQUENCE trial

Tim Raine, Silvio Danese, Stefan Schreiber, Xiang Gao et autres

Background: Corticosteroid (CS) dependency and/or resistance occurs in approximately 50% of patients with Crohn’s disease (CD). 1 In SEQUENCE, risankizumab (RZB; interleukin [IL]-23 inhibitor) demonstrated superiority over ustekinumab (UST; IL-12/IL-23 inhibitor) for the ranked secondary endpoints of CS-free clinical remission and CS-free …

gb, it, de, cn, ph, pt, us (code pays fourni par la source)

Efficacy of Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor, in Scalp Psoriasis by Baseline Psoriasis Area and Severity Index (PASI) and Baseline Body Surface Area (BSA): A Subanalysis of the Phase 3 Clinical Trial Data

Andrew Blauvelt, Howard L. Sofen, Jo Lambert, Joseph Frank Merola et autres

Introduction: Deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, is approved in the US, EU, and other countries for treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy. Deucravacitinib was effective and well tolerated in the global, …

us, be (code pays fourni par la source)

Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor)

Melinda Gooderham, Ronald B. Vender, Jeffrey Crowley, Hwanhee Hong et autres

When assessing the effect of a therapy for psoriasis (PsO), it is important to consider speed of response and cumulative response. However, responses among biologics may differ by body regions. This post hoc analysis compares speed of response and cumulative response for …

ca, us (code pays fourni par la source)

Efficacy of long‐term risankizumab treatment for moderate‐to‐severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks ( LIMMitless trial)

Bruce E Strober, Hervé Bachelez, Jeffrey Crowley, Boni Elizabeth Elewski et autres

BACKGROUND: Psoriasis is an inflammatory skin disease that impacts a heterogeneous group of patients and can have multiple clinical manifestations. Risankizumab is approved for the treatment of moderate-to-severe plaque psoriasis. OBJECTIVES: To evaluate the long-term efficacy of risankizumab according to baseline patient …

us, fr, ca, at (code pays fourni par la source)

DOP53 Long-term Efficacy and Safety of Risankizumab in Patients With Moderate to Severe Crohn's Disease up to 3 Years of Treatment: Results From the FORTIFY Open-Label Long-term Extension

Marc Ferrante, Remo Panaccione, Jean‐Frédéric Colombel, Marla C. Dubinsky et autres

Abstract Background The ongoing FORTIFY maintenance open-label extension (OLE) substudy evaluates the long-term efficacy and safety of risankizumab (RZB), a p19 interleukin-23 inhibitor, for treatment of moderate to severe Crohn’s disease (CD). Here, we report 2-year results of FORTIFY OLE. Methods The …

be, ca, us, jp, gb, nl (code pays fourni par la source)

DOP18 Efficacy of risankizumab versus ustekinumab by baseline Crohn’s Disease location: post-hoc analysis of the SEQUENCE head-to-head trial

Laurent Peyrin‐Biroulet, Jean Fred Colombel, Geert D’Haens, Marla C. Dubinsky et autres

Abstract Background In Crohn’s disease (CD), disease location may impact treatment effect. This post-hoc analysis of the SEQUENCE head-to-head trial (NCT04524611) compared the efficacy of risankizumab (RZB), an interleukin (IL)-23 p19 inhibitor, versus ustekinumab (UST), an IL-12/23 p40 inhibitor, by CD location. …

fr, us, nl, cn, ca (code pays fourni par la source)

P1081 Pharmacokinetics and immunogenicity of the ustekinumab biosimilar candidate ABP 654 in patients with moderate-to-severe plaque psoriasis

Vincent Chow, Daniel T. Mytych, Andrew Blauvelt, Kim Alexander Papp et autres

Abstract Background ABP 654 is being developed as a biosimilar candidate to ustekinumab reference product (RP), a biologic agent used in the treatment of certain chronic, immune-mediated, inflammatory diseases. Previously, we reported no clinically meaningful differences in efficacy or safety between ABP …

us, ca (code pays fourni par la source)

44102 Risankizumab Efficacy for Moderate-to-Severe Plaque Psoriasis over 256 Weeks in Patients with Prior Biologic Treatments

Jeffrey Crowley, Chih-ho Hong, Melinda Gooderham, Georgios Kokolakis et autres

ca, de, us (code pays fourni par la source)

42664 Itching in patients with moderate to severe plaque psoriasis: The relationship between improvements in Psoriasis Area and Severity Index and patient-reported symptoms in the BE RADIANT phase 3b trial

Matthias Augustin, Richard G B Langley, Richard Bruce Warren, Mark Lebwohl et autres

de, ca, gb, us, be (code pays fourni par la source)